Float Short %

9.26

Margin Of Safety %

Put/Call OI Ratio

0.47

EPS Next Q Diff

-0.04

EPS Last/This Y

-1.96

EPS This/Next Y

-0.94

Price

117.63

Target Price

108.58

Analyst Recom

Performance Q

122.03

Relative Volume

0.77

Beta

Ticker: RVMD

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	RVMD	80.72	0.16	2.49	39803
2025-12-29	RVMD	80.55	0.16	1.59	40011
2025-12-30	RVMD	79.67	0.16	0.57	40162
2025-12-31	RVMD	79.67	0.17	0.32	40451
2026-01-02	RVMD	79.02	0.17	2.54	40436
2026-01-05	RVMD	78.34	0.17	0.64	40789
2026-01-06	RVMD	79.8	0.17	0.30	40829
2026-01-07	RVMD	86.35	0.17	0.49	40800
2026-01-08	RVMD	107.42	0.24	0.39	50317
2026-01-09	RVMD	118.4	0.23	0.43	62979
2026-01-12	RVMD	117.06	0.32	0.72	98673
2026-01-13	RVMD	119.82	0.40	0.94	114458
2026-01-14	RVMD	121.2	0.42	0.78	119259
2026-01-15	RVMD	123.31	0.46	0.43	124636
2026-01-16	RVMD	120.52	0.47	2.38	125439
2026-01-20	RVMD	116.16	0.54	0.29	89535
2026-01-21	RVMD	117.52	0.52	0.07	102481
2026-01-22	RVMD	118.81	0.48	0.20	109284
2026-01-23	RVMD	117.69	0.47	0.18	114772
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	RVMD	80.74	-42.4	-256.5	-5.54
2025-12-29	RVMD	80.53	-42.4	-260.5	-5.54
2025-12-30	RVMD	79.68	-42.4	-249.2	-5.54
2025-12-31	RVMD	79.67	-42.4	-264.1	-5.54
2026-01-02	RVMD	79.01	-42.4	-252.8	-5.54
2026-01-05	RVMD	78.32	-42.4	-251.7	-5.54
2026-01-06	RVMD	79.81	-42.4	-294.4	-5.54
2026-01-07	RVMD	88.00	-42.4	-414.8	-5.54
2026-01-08	RVMD	107.36	-39.8	-329.4	-5.54
2026-01-09	RVMD	118.79	-39.8	-415.9	-5.54
2026-01-12	RVMD	117.14	-39.8	-246.8	-5.54
2026-01-13	RVMD	119.91	-39.8	-297.7	-5.54
2026-01-14	RVMD	121.09	-39.8	-278.0	-5.54
2026-01-15	RVMD	123.26	-39.8	-288.3	-5.54
2026-01-16	RVMD	120.28	-39.8	-230.5	-5.54
2026-01-20	RVMD	116.18	-39.8	-216.6	-5.54
2026-01-21	RVMD	117.52	-39.8	-280.8	-5.54
2026-01-22	RVMD	118.79	-39.8	-280.5	-5.54
2026-01-23	RVMD	117.63	-39.8	-250.6	-5.54
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	RVMD	-1.37	1.24	9.12
2025-12-29	RVMD	-1.37	1.24	9.12
2025-12-30	RVMD	-1.37	1.24	9.12
2025-12-31	RVMD	-1.37	1.24	9.12
2026-01-02	RVMD	-1.37	1.24	9.12
2026-01-05	RVMD	-1.37	1.24	9.12
2026-01-06	RVMD	-1.37	1.24	9.12
2026-01-07	RVMD	-1.37	1.24	9.12
2026-01-08	RVMD	-1.37	1.24	9.12
2026-01-09	RVMD	-1.66	1.24	9.12
2026-01-12	RVMD	-1.83	1.23	9.12
2026-01-13	RVMD	-1.66	1.23	9.26
2026-01-14	RVMD	-1.66	1.23	9.26
2026-01-15	RVMD	-1.66	1.23	9.26
2026-01-16	RVMD	-1.66	1.23	9.26
2026-01-20	RVMD	-1.66	2.01	9.26
2026-01-21	RVMD	-1.66	2.01	9.26
2026-01-22	RVMD	-1.66	2.01	9.26
2026-01-23	RVMD	-1.66	2.01	9.26
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-1.61

Avg. EPS Est. Current Quarter

-1.6

Avg. EPS Est. Next Quarter

-1.65

Insider Transactions

-1.66

Institutional Transactions

2.01

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

5.5

Max Drawdown 5-Year %

-73.3

Target Price

108.58

P/E

Forward P/E

PEG

P/S

P/B

13.97

P/Free Cash Flow

EPS

-5.18

Average EPS Est. Cur. Y

-5.54

EPS Next Y. (Est.)

-6.48

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.77

Return on Equity vs Sector %

-87.4

Return on Equity vs Industry %

-71.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

-250.6

Revolution Medicines, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 809

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

stock quote shares RVMD – Revolution Medicines, Inc. Stock Price stock today

news today RVMD – Revolution Medicines, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RVMD – Revolution Medicines, Inc. yahoo finance google finance

stock history RVMD – Revolution Medicines, Inc. invest stock market

stock prices RVMD premarket after hours

ticker RVMD fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: RVMD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y